Search Bar & Filters
Found 13 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the efficacy and safety of orelabrutinib, a brain-penetrating BTK inhibitor, in people with Primary Progressive Multiple Sclerosis PPMS. This is a Phase 3, randomized, double-blind, parallel-group, multicenter study comparing orelabrutinib with a placebo. Approximately 705 participants aged 18 to 60 with documented disability progression will be enrolled globally. Participants will be randomly assigned in a 21 ratio to receive either oral orelabrutinib or a placebo. Treatment will last approximately 30 to 60 months, with a minimum duration of 12 months. The study includes two groups one receiving orelabrutinib and the other receiving placebo, both taken orally. Throughout the study, participants will undergo regular assessments including disability progression measurements confirmed over 12 and 24 weeks, MRI scans, and tests such as the 9-hole Peg Test and Timed 25-Foot Walk Test. Safety will be monitored continuously, and the primary outcome is time to confirmed disability progression over about 120 weeks. Participants will be followed up for up to 5 years to evaluate the treatment effects and safety.
Actively Recruiting
Researchers are evaluating a special type of multisystemic therapy called MST-ID for adolescents aged 10 to 19 with severe behavioural problems living in families affected by intellectual disability ID. The study compares MST-ID to standard multisystemic therapy MST to see if MST-ID is better at reducing rule-breaking and other behavioural issues. The study uses both numbers-based assessments and families personal experiences to understand treatment effects and is sponsored by De Viersprong. The treatments involved are intensive, home-based therapies with 3 to 5 home visits each week over about three to five months. Both MST and MST-ID target adolescents behavioural problems by involving their family, school, and social environments. MST-ID differs by adapting its approach to the needs of families with ID, using simpler language, more structured sessions, and extra practice time to help families apply what they learn. Families receive either standard MST or the MST-ID specialization following usual referrals. Participants complete questionnaires at five time points start of treatment, end of treatment, and three follow-ups at 6, 12, and 18 months after treatment. Data collection includes standard MST monitoring and special interviews or discussions to capture families experiences. Researchers measure rule-breaking behaviour, other behavioural problems, parenting stress, out-of-home placements, school or work status, addictions, social networks, parenting skills, family relations, social support, and adolescent success with peers and education or work. The study lasts over 18 months with ongoing assessments to track impact.
Actively Recruiting
Researchers are investigating whether taking breaks from the standard combination therapy of daratumumab, lenalidomide, and dexamethasone Dara-Rd for newly diagnosed multiple myeloma patients affects survival and quality of life. This study aims to compare continuous treatment versus planned treatment-free intervals to see if stopping therapy temporarily may reduce side effects, allow recovery from toxicity, and improve overall well-being while controlling the disease. Participants who have completed 12 cycles of Dara-Rd with at least a partial response and no signs of disease progression will be randomly assigned to one of two groups. One group will continue Dara-Rd therapy without interruption until disease progression, while the other group will stop treatment temporarily and restart it at biochemical progression, continuing until disease progression. The trial is open-label and will follow patients for several years to assess outcomes. Throughout the study, researchers will monitor participants event-free survival and progression-free survival for up to about 57 and 69 months, respectively. Additional assessments include side effect burden, patient-reported quality of life, treatment costs, treatment-free interval length, response times, and survival after second-line therapy. Regular evaluations will help determine how treatment interruption affects toxicity, dose intensity, and overall treatment outcomes over the long term.
Actively Recruiting
Researchers are evaluating the effects of low-load blood flow restriction training LL-BFRT compared to heavy-load resistance training HLRT on graft maturity after anterior cruciate ligament ACL reconstruction using a bone-patellar tendon-bone graft. The study aims to understand whether LL-BFRT offers benefits or risks during rehabilitation by measuring MRI-based graft maturity as well as other factors like knee stability, range of motion, muscle strength, and patient satisfaction. Participants will be randomly assigned to one of two groups. The LL-BFRT group will perform biweekly strength training for 12 weeks starting two weeks after surgery, using a specialized tourniquet system to restrict blood flow during exercises such as leg press, leg extension, deadlift, and squats at 30% of their one-repetition maximum. The HLRT resistance training group will also train biweekly for 12 weeks, performing similar exercises but with heavier loads up to 70% of their one-repetition maximum without blood flow restriction. During the study, participants will be assessed at three and nine months after surgery with MRI scans to measure graft maturity and other evaluations including knee range of motion, stability, pain, function, muscle strength, and return to pre-injury sports level. Safety and feasibility of the rehabilitation methods will be monitored throughout. The total participation spans at least nine months to capture the main outcomes and recovery progress.
Actively Recruiting
Researchers are evaluating an Integrated Oncological Decision-making Model IODM designed to tailor cancer treatment plans to individual patients. This study aims to assess how the IODM affects personalized treatment decisions and patient outcomes. The trial uses a stepped-wedge cluster randomized design involving 400 adult patients across eight oncological care paths in four medical centers in the Netherlands. Participants will receive either usual care based on standard clinical guidelines or care using the IODM, which integrates three components current oncological treatment options with their benefits and risks, the patients overall health including physical and emotional functioning, and the patients goals and preferences in treatment and daily life. The study transitions care paths from standard practice to the IODM in randomized steps. Throughout the study, researchers will assess the difference between standard treatment recommendations and actual decisions, focusing on whether these differences reflect more personalized choices. They will also evaluate patient quality of life, frailty, resilience, optimism, decision-making preferences, and patient-centeredness using questionnaires and medical records. The study duration includes the intervention and a 12-month follow-up, totaling around two years.
Actively Recruiting
Researchers are investigating the effectiveness of adding liothyronine LT3 to levothyroxine LT4 treatment in patients with autoimmune hypothyroidism who continue to experience severe tiredness despite having normalized thyroid hormone levels on LT4 alone. This study addresses the problem that LT4 monotherapy may not fully replicate the natural balance of thyroid hormones, as healthy individuals produce some T3 directly. The trial also explores whether certain genetic factors influence response to combination therapy. The study begins with a run-in period where all participants switch to a standardized generic LT4 to stabilize thyroid hormone levels. After confirming normal TSH levels and persistent tiredness, participants enter a one-year randomized, double-blind trial comparing LT4LT3 combination therapy to LT4 with placebo. The LT4LT3 group takes LT4 once daily and LT3 twice daily at a set ratio. Visits occur at baseline and multiple times over the year to adjust doses and monitor health. Participants undergo physical exams, ECGs, blood tests, and complete questionnaires about tiredness, quality of life, and medical resource use throughout the study. Additional measures include bone markers, scans, cardiovascular and metabolic assessments, and neurocognitive tests in subgroups. The main outcome is the change in tiredness scores over 52 weeks, with safety and genetic factors also evaluated. The total study duration includes the run-in and treatment phases, lasting several months to over a year.
Actively Recruiting
Researchers are investigating cachexia, a syndrome involving significant loss of body weight and muscle mass that affects cancer patients quality of life, survival, and treatment outcomes. The study aims to improve the accuracy of cachexia diagnosis by comparing self-reported weight changes with objective measurements taken before treatment. This pilot study involves patients aged 18 and older undergoing curative-intent chemotherapy or surgery for various cancers, including upper gastrointestinal, hepatobiliary, pancreatic, colorectal, and ovarian cancers. Participants will undergo extensive pre-treatment assessments including physical tests, body measurements, and laboratory tests. They will receive a weight scale and an accelerometer to measure daily body weight and physical activity at home. For chemotherapy patients, monitoring starts at initial clinic presentation, continues through treatment, and ends two weeks after chemotherapy. For surgical patients, monitoring pauses during hospital stay and resumes after discharge until follow-up. Imaging and body composition analyses will be performed before and after treatment. Throughout the study, researchers will record treatment-related adverse events, response to therapy, survival, and disease-free survival for up to five years. Physical activity, body composition, and other cachexia-related parameters will also be analyzed. Data will be collected via tests, scans, questionnaires, and equipment use, with adverse events classified by established criteria. This comprehensive monitoring aims to better understand cachexias impact and improve diagnosis accuracy in cancer care.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of two drug combinations for treating patients with hormone receptor-positive, HER2-negative advanced breast cancer that has a PIK3CA mutation. This phase 3, open-label, global study compares RLY-2608 zovegalisib plus fulvestrant against capivasertib plus fulvestrant following disease recurrence or progression after prior treatment with a CDK46 inhibitor. The study focuses on patients whose cancer has advanced locally or metastasized and have specific genetic mutations influencing treatment response. Participants will receive one of two treatment combinations zovegalisib taken orally twice daily together with fulvestrant given by intramuscular injection on specified days in a 28-day cycle, or capivasertib taken orally twice daily on an intermittent weekly schedule combined with the same fulvestrant regimen. Treatment cycles repeat every 28 days. The study will monitor and compare these combinations over several months to assess outcomes. Throughout the study, participants will undergo regular assessments including imaging scans to measure cancer progression, blood tests to monitor drug levels, and questionnaires to evaluate quality of life. Researchers will track progression-free survival, overall survival, response rates, duration of response, clinical benefit, and safety profiles. The study duration may extend up to approximately 77 months, with ongoing monitoring of health status and adverse events to gather comprehensive data on treatment impact.
Actively Recruiting
Researchers are investigating whether dexrazoxane can prevent heart damage caused by anthracycline chemotherapy in patients with diffuse large B-cell lymphoma DLBCL. This condition, known as anthracycline-induced cardiac dysfunction AICD, can lead to irreversible heart muscle damage and heart failure. Patients with DLBCL are at higher risk of AICD due to their treatment regimen and longer survival, making prevention of heart damage important. This is a national phase III randomized controlled trial conducted across multiple hospitals in the Netherlands. Participants will receive six cycles of R-CHOP21 chemotherapy, which includes rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone. They will be randomly assigned to either receive dexrazoxane intravenously before doxorubicin infusion or to receive standard treatment without dexrazoxane. Some patients with double hit lymphoma may receive lenalidomide as part of their regimen. The trial does not use placebo due to the nature of dexrazoxane. Cardiac function will be monitored using echocardiography before treatment and at 4 and 12 months after treatment starts. Participants will undergo heart function tests, metabolic remission assessments, survival evaluations, blood biomarker tests, and quality of life questionnaires during the study. The main outcome is the occurrence of significant heart function decline within 12 months. The study will also assess whether dexrazoxane affects cancer treatment effectiveness. Participants will be followed for at least one year to monitor heart health and cancer status, with regular visits for evaluations and treatment administration.
Actively Recruiting
This research aims to create a nationwide group of bladder cancer patients in the Netherlands, including those with high-risk non-muscle-invasive, muscle-invasive, and metastatic stages. It focuses on gathering information to support both observational and interventional bladder cancer research. The study is sponsored by the Prospective Bladder Cancer Infrastructure Foundation and includes adults diagnosed with bladder cancer at any stage except Ta. Participants are observed over a long period, with no specific treatments or interventions assigned by the study. The infrastructure supports collecting data to study overall survival over 10 years as the primary outcome. Secondary outcomes include progression-free survival, recurrence-free survival over 10 years, and health-related quality of life assessments for 2 years. During the study, participants will have their health and cancer status monitored, and quality of life will be evaluated. Data collection may involve questionnaires and medical records over the study period. The study plans to follow participants until the end date in 2041, with a primary completion date set for the end of 2040.
1-10 of 13
1